Tumor Lysis Syndrome following a Single Dose of Nivolumab for Relapsed Small-Cell Lung Cancer
This report highlights the potential risk of development of TLS with checkpoint inhibitor therapy.Case Rep Oncol 2021;14:1652 –1659
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Emergency Medicine | Hematology | Hospitals | Immunotherapy | Liver | Lung Cancer | Pain | Renal Failure | Small Cell Lung Cancer | Sodium | Urology & Nephrology